公开(公告)号：US08168179B2

公开(公告)日：2012-05-01

申请号：US12538698

申请日：2009-08-10

申请人： Tasuku Honjo ,  Nagahiro Minato ,  Yoshiko Iwai ,  Shiro Shibayama

发明人： Tasuku Honjo ,  Nagahiro Minato ,  Yoshiko Iwai ,  Shiro Shibayama

IPC分类号： A61K39/395

CPC分类号： C07K16/2818 ,  A61K9/0019 ,  A61K31/7088 ,  A61K38/1774 ,  A61K38/212 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/02 ,  A61K47/26 ,  A61K2039/505 ,  A61K2039/507 ,  C07K14/70521 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/30 ,  C12Q1/025 ,  G01N33/5011 ,  G01N33/574 ,  G01N2500/00 ,  Y02A50/39 ,  Y02A50/394 ,  Y02A50/463 ,  Y02A50/466

摘要： Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that select the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for treatment of cancer or infection.

摘要翻译： 通过由PD-1，PD-L1或PD-L2诱导的免疫抑制信号的抑制和使用它们的疗法，包括作为活性成分的免疫增强底物，用于癌症或感染的底物的筛选方法由免疫增强引起的癌症或感染治疗的组合物 治疗，用于筛选方法的细胞系，选择用于癌症治疗的底物的评价方法和用于评价方法的癌细胞移植的哺乳动物。 抑制PD-1，PD-L1或PD-L2的功能的本发明的组合物可用于治疗癌症或感染。

公开(公告)号：US20090297518A1

公开(公告)日：2009-12-03

申请号：US12538698

申请日：2009-08-10

申请人： Tasuku Honjo ,  Nagahiro Minato ,  Yoshiko Iwai ,  Shiro Shibayama

发明人： Tasuku Honjo ,  Nagahiro Minato ,  Yoshiko Iwai ,  Shiro Shibayama

IPC分类号： A61K39/395 ,  A61P31/18 ,  A61P31/12

CPC分类号： C07K16/2818 ,  A61K9/0019 ,  A61K31/7088 ,  A61K38/1774 ,  A61K38/212 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/02 ,  A61K47/26 ,  A61K2039/505 ,  A61K2039/507 ,  C07K14/70521 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/30 ,  C12Q1/025 ,  G01N33/5011 ,  G01N33/574 ,  G01N2500/00 ,  Y02A50/39 ,  Y02A50/394 ,  Y02A50/463 ,  Y02A50/466

摘要： Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that select the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for treatment of cancer or infection.

摘要翻译： 通过由PD-1，PD-L1或PD-L2诱导的免疫抑制信号的抑制和使用它们的疗法，包括作为活性成分的免疫增强底物，用于癌症或感染的底物的筛选方法由免疫增强引起的癌症或感染治疗的组合物 治疗，用于筛选方法的细胞系，选择用于癌症治疗的底物的评价方法和用于评价方法的癌细胞移植的哺乳动物。 抑制PD-1，PD-L1或PD-L2的功能的本发明的组合物可用于治疗癌症或感染。

公开(公告)号：US08728474B2

公开(公告)日：2014-05-20

申请号：US12959307

申请日：2010-12-02

申请人： Tasuku Honjo ,  Nagahiro Minato ,  Yoshiko Iwai ,  Shiro Shibayama

发明人： Tasuku Honjo ,  Nagahiro Minato ,  Yoshiko Iwai ,  Shiro Shibayama

IPC分类号： A61K39/395

CPC分类号： C07K16/2818 ,  A61K9/0019 ,  A61K31/7088 ,  A61K38/1774 ,  A61K38/212 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/02 ,  A61K47/26 ,  A61K2039/505 ,  A61K2039/507 ,  C07K14/70521 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/30 ,  C12Q1/025 ,  G01N33/5011 ,  G01N33/574 ,  G01N2500/00 ,  Y02A50/39 ,  Y02A50/394 ,  Y02A50/463 ,  Y02A50/466

摘要： Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that select the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for treatment of cancer or infection.

摘要翻译： 通过由PD-1，PD-L1或PD-L2诱导的免疫抑制信号的抑制和使用它们的疗法，包括作为活性成分的免疫增强底物，用于癌症或感染的底物的筛选方法由免疫增强引起的癌症或感染治疗的组合物 治疗，用于筛选方法的细胞系，选择用于癌症治疗的底物的评价方法和用于评价方法的癌细胞移植的哺乳动物。 抑制PD-1，PD-L1或PD-L2的功能的本发明的组合物可用于治疗癌症或感染。

公开(公告)号：US07595048B2

公开(公告)日：2009-09-29

申请号：US10519925

申请日：2003-07-02

申请人： Tasuku Honjo ,  Nagahiro Minato ,  Yoshiko Iwai ,  Shiro Shibayama

发明人： Tasuku Honjo ,  Nagahiro Minato ,  Yoshiko Iwai ,  Shiro Shibayama

IPC分类号： A61K39/395 ,  C07K16/28

CPC分类号： C07K16/2818 ,  A61K9/0019 ,  A61K31/7088 ,  A61K38/1774 ,  A61K38/212 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/02 ,  A61K47/26 ,  A61K2039/505 ,  A61K2039/507 ,  C07K14/70521 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/30 ,  C12Q1/025 ,  G01N33/5011 ,  G01N33/574 ,  G01N2500/00 ,  Y02A50/39 ,  Y02A50/394 ,  Y02A50/463 ,  Y02A50/466

摘要： Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of the immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that select the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibit the function of PD-1, PD-L1, or PD-L2 are useful for treatment of cancer or infection.

摘要翻译： 通过由PD-1，PD-L1或PD-L2诱导的免疫抑制信号的抑制和使用它们的疗法，包括作为活性成分的免疫增强底物，用于癌症的底物的筛选方法或通过免疫增强 感染治疗，用于筛选方法的细胞系，选择用于癌症治疗的底物的评价方法和用于评价方法的癌细胞移植的哺乳动物。 抑制PD-1，PD-L1或PD-L2功能的本发明的组合物可用于治疗癌症或感染。

公开(公告)号：US20060110383A1

公开(公告)日：2006-05-25

申请号：US10519925

申请日：2003-07-02

申请人： Tasuku Honjo ,  Nagahiro Minato ,  Yoshiko Iwai ,  Shiro Shibayama

发明人： Tasuku Honjo ,  Nagahiro Minato ,  Yoshiko Iwai ,  Shiro Shibayama

IPC分类号： A61K39/395 ,  A61K38/17 ,  A61K48/00

CPC分类号： C07K16/2818 ,  A61K9/0019 ,  A61K31/7088 ,  A61K38/1774 ,  A61K38/212 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/02 ,  A61K47/26 ,  A61K2039/505 ,  A61K2039/507 ,  C07K14/70521 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/30 ,  C12Q1/025 ,  G01N33/5011 ,  G01N33/574 ,  G01N2500/00 ,  Y02A50/39 ,  Y02A50/394 ,  Y02A50/463 ,  Y02A50/466

摘要： Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for cancer or infection treatment.

公开(公告)号：US20110081341A1

公开(公告)日：2011-04-07

申请号：US12959307

申请日：2010-12-02

申请人： Tasuku HONJO ,  Nagahiro Minato ,  Yoshiko Iwai ,  Shiro Shibayama

发明人： Tasuku HONJO ,  Nagahiro Minato ,  Yoshiko Iwai ,  Shiro Shibayama

IPC分类号： A61K39/395 ,  A61P31/00 ,  A61P35/00

CPC分类号： C07K16/2818 ,  A61K9/0019 ,  A61K31/7088 ,  A61K38/1774 ,  A61K38/212 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/02 ,  A61K47/26 ,  A61K2039/505 ,  A61K2039/507 ,  C07K14/70521 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/30 ,  C12Q1/025 ,  G01N33/5011 ,  G01N33/574 ,  G01N2500/00 ,  Y02A50/39 ,  Y02A50/394 ,  Y02A50/463 ,  Y02A50/466

摘要： Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that select the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for treatment of cancer or infection.

摘要翻译： 通过由PD-1，PD-L1或PD-L2诱导的免疫抑制信号的抑制和使用它们的疗法，包括作为活性成分的免疫增强底物，用于癌症或感染的底物的筛选方法由免疫增强引起的癌症或感染治疗的组合物 治疗，用于筛选方法的细胞系，选择用于癌症治疗的底物的评价方法和用于评价方法的癌细胞移植的哺乳动物。 抑制PD-1，PD-L1或PD-L2的功能的本发明的组合物可用于治疗癌症或感染。

公开(公告)号：US08574872B2

公开(公告)日：2013-11-05

申请号：US13486189

申请日：2012-06-01

申请人： Nagahiro Minato ,  Yoshimasa Tanaka ,  Shiro Shibayama

发明人： Nagahiro Minato ,  Yoshimasa Tanaka ,  Shiro Shibayama

IPC分类号： C12P21/04 ,  C07K14/00

CPC分类号： C07K14/70503 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/00 ,  A61K47/26 ,  C07K14/70532 ,  Y02A50/465 ,  Y02A50/481

摘要： As a substance which pharmacologically regulates the function of a cell surface functional molecule, a substance which has specificity and an activity or efficacy equal or superior to an antibody and does not require an advanced production technique and facility for application thereof to a pharmaceutical product has been demanded. The invention relates to a multimer of an extracellular domain of a cell surface functional molecule, particularly a tetramer of an extracellular domain of PD-1 or PD-L1. Further, the invention relates to an application of such a tetramer as a preventive and/or therapeutic agent for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of PD-1 or PD-L1 as a testing or diagnostic agent or a research agent for such a disease.

摘要翻译： 作为药理学上调节细胞表面功能分子的功能的物质，具有特异性，活性或功效等同于或优于抗体且不需要先进的生产技术的物质及其应用于药物的设备已经被 要求 本发明涉及细胞表面功能分子的细胞外结构域的多聚体，特别是PD-1或PD-L1细胞外结构域的四聚体。 此外，本发明涉及这样的四聚体作为癌症，癌症转移，免疫缺陷，感染性疾病等的预防和/或治疗剂的应用，以及应用PD-1或PD-L1作为检测或诊断 代理人或这种疾病的研究代理人。

公开(公告)号：US20120269859A1

公开(公告)日：2012-10-25

申请号：US13486189

申请日：2012-06-01

申请人： Nagahiro Minato ,  Yoshimasa Tanaka ,  Shiro Shibayama

发明人： Nagahiro Minato ,  Yoshimasa Tanaka ,  Shiro Shibayama

IPC分类号： C07K14/435 ,  A61P35/00 ,  A61K39/00 ,  A61P37/00 ,  A61P31/00 ,  A61K38/17 ,  A61P35/04

CPC分类号： C07K14/70503 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/00 ,  A61K47/26 ,  C07K14/70532 ,  Y02A50/465 ,  Y02A50/481

摘要： As a substance which pharmacologically regulates the function of a cell surface functional molecule, a substance which has specificity and an activity or efficacy equal or superior to an antibody and does not require an advanced production technique and facility for application thereof to a pharmaceutical product has been demanded. The invention relates to a multimer of an extracellular domain of a cell surface functional molecule, particularly a tetramer of an extracellular domain of PD-1 or PD-L1. Further, the invention relates to an application of such a tetramer as a preventive and/or therapeutic agent for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of PD-1 or PD-L1 as a testing or diagnostic agent or a research agent for such a disease.

摘要翻译： 作为药理学上调节细胞表面功能分子的功能的物质，具有特异性，活性或功效等同于或优于抗体且不需要先进的生产技术的物质及其应用于药物的设备已经被 要求 本发明涉及细胞表面功能分子的细胞外结构域的多聚体，特别是PD-1或PD-L1细胞外结构域的四聚体。 此外，本发明涉及这样的四聚体作为癌症，癌症转移，免疫缺陷，感染性疾病等的预防和/或治疗剂的应用，以及应用PD-1或PD-L1作为检测或诊断 代理人或这种疾病的研究代理人。

公开(公告)号：US08216996B2

公开(公告)日：2012-07-10

申请号：US12281427

申请日：2007-03-02

申请人： Nagahiro Minato ,  Yoshimasa Tanaka ,  Shiro Shibayama

发明人： Nagahiro Minato ,  Yoshimasa Tanaka ,  Shiro Shibayama

IPC分类号： A61K38/00

CPC分类号： C07K14/70503 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/00 ,  A61K47/26 ,  C07K14/70532 ,  Y02A50/465 ,  Y02A50/481

摘要： As a substance which pharmacologically regulates the function of a cell surface functional molecule, a substance which has specificity and an activity or efficacy equal or superior to an antibody and does not require an advanced production technique and facility for application thereof to a pharmaceutical product has been demanded. The invention relates to a multimer of an extracellular domain of a cell surface functional molecule, particularly a tetramer of an extracellular domain of PD-1 or PD-L1. Further, the invention relates to an application of such a tetramer as a preventive and/or therapeutic agent for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of PD-1 or PD-L1 as a testing or diagnostic agent or a research agent for such a disease.

摘要翻译： 作为药理学上调节细胞表面功能分子的功能的物质，具有特异性，活性或功效等同于或优于抗体且不需要先进的生产技术的物质及其应用于药物的设备已经被 要求 本发明涉及细胞表面功能分子的细胞外结构域的多聚体，特别是PD-1或PD-L1细胞外结构域的四聚体。 此外，本发明涉及这样的四聚体作为癌症，癌症转移，免疫缺陷，感染性疾病等的预防和/或治疗剂的应用，以及应用PD-1或PD-L1作为检测或诊断 代理人或这种疾病的研究代理人。

公开(公告)号：US20090305950A1

公开(公告)日：2009-12-10

申请号：US12281427

申请日：2007-03-02

申请人： Nagahiro Minato ,  Yoshimasa Tanaka ,  Shiro Shibayama

发明人： Nagahiro Minato ,  Yoshimasa Tanaka ,  Shiro Shibayama

IPC分类号： A61K38/16 ,  C07K14/00 ,  C07H21/00 ,  C07H21/04 ,  C12N15/63 ,  C12N5/10 ,  C12P21/02

CPC分类号： C07K14/70503 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/00 ,  A61K47/26 ,  C07K14/70532 ,  Y02A50/465 ,  Y02A50/481

摘要： As a substance which pharmacologically regulates the function of a cell surface functional molecule, a substance which has specificity and an activity or efficacy equal or superior to an antibody and does not require an advanced production technique and facility for application thereof to a pharmaceutical product has been demanded. The invention relates to a multimer of an extracellular domain of a cell surface functional molecule, particularly a tetramer of an extracellular domain of PD-1 or PD-L1. Further, the invention relates to an application of such a tetramer as a preventive and/or therapeutic agent for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of PD-1 or PD-L1 as a testing or diagnostic agent or a research agent for such a disease.

摘要翻译： 作为药理学上调节细胞表面功能分子的功能的物质，具有特异性，活性或功效等同于或优于抗体且不需要先进的生产技术的物质及其应用于药物的设备已经被 要求 本发明涉及细胞表面功能分子的细胞外结构域的多聚体，特别是PD-1或PD-L1细胞外结构域的四聚体。 此外，本发明涉及这样的四聚体作为癌症，癌症转移，免疫缺陷，感染性疾病等的预防和/或治疗剂的应用，以及应用PD-1或PD-L1作为检测或诊断 代理人或这种疾病的研究代理人。